{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:52:46Z","timestamp":1790722366374,"version":"4.1.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","joms.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Oral and Maxillofacial Surgery"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.joms.2020.10.001","type":"journal-article","created":{"date-parts":[[2020,10,10]],"date-time":"2020-10-10T11:18:14Z","timestamp":1602328694000},"page":"598-607","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Adjuvant Alendronic Acid in the Management of Severe Cherubism: A Case Report and Literature Review"],"prefix":"10.1016","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0091-7578","authenticated-orcid":false,"given":"Daniel","family":"Bradley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3709-5619","authenticated-orcid":false,"given":"Vinod","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calum","family":"Honeyman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"McGurk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.joms.2020.10.001_bib1","article-title":"Cherubism: a systematic literature review of clinical and molecular aspects","author":"Chrcanovic","year":"2020","journal-title":"Int J Oral Maxollofac Surg"},{"key":"10.1016\/j.joms.2020.10.001_bib2","first-page":"1","article-title":"Positive outcomes of denosumab treatment in 2 patients with cherubism","author":"Bar Droma","year":"2020","journal-title":"J Oral Maxillofac Surg"},{"issue":"Suppl 1","key":"10.1016\/j.joms.2020.10.001_bib3","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1186\/1750-1172-7-S1-S6","article-title":"Cherubism: Best clinical practice","volume":"7","author":"Papadaki","year":"2012","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.joms.2020.10.001_bib4","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1158\/ajc.1933.946","article-title":"Familial multilocular cystic disease of the jaws","volume":"17","author":"Jones","year":"1933","journal-title":"Am J Cancer"},{"key":"10.1016\/j.joms.2020.10.001_bib5","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/j.joms.2006.06.266","article-title":"Cherubism treated with calcitonin: Report of a case","volume":"65","author":"de Lange","year":"2007","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.joms.2020.10.001_bib6","series-title":"Genereviews\u00ae","article-title":"Cherubism","author":"Kannu","year":"2018"},{"key":"10.1016\/j.joms.2020.10.001_bib7","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1054\/bjps.2001.3701","article-title":"Cherubism and its charlatans","volume":"54","author":"Lannon","year":"2001","journal-title":"Br J Plast Surg"},{"key":"10.1016\/j.joms.2020.10.001_bib8","first-page":"4656","article-title":"Cherubism misdiagnosed as giant cell tumor: A case report and review of literature","volume":"8","author":"Jiao","year":"2015","journal-title":"Int J Clin Exp Med"},{"key":"10.1016\/j.joms.2020.10.001_bib9","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/0030-4220(93)90287-E","article-title":"Vascular transformation in cherubism. Oral Surgery","volume":"76","author":"Koury","year":"1993","journal-title":"Oral Med Oral Pathol"},{"key":"10.1016\/j.joms.2020.10.001_bib10","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1097\/01.sap.0000248141.36904.19","article-title":"Two-stage surgical treatment of severe cherubism","volume":"58","author":"Raposo-Amaral","year":"2007","journal-title":"Ann Plast Surg"},{"key":"10.1016\/j.joms.2020.10.001_bib11","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/s13023-018-0907-2","article-title":"Molecular and cellular characterizations of human cherubism: Disease aggressiveness depends on osteoclast differentiation","volume":"13","author":"Kadlub","year":"2018","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.joms.2020.10.001_bib12","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.cell.2006.10.047","article-title":"Increased myeloid cell responses to M-CSF and RANKL cause bone loss and inflammation in SH3BP2 \u201ccherubism\u201d mice","volume":"128","author":"Ueki","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.joms.2020.10.001_bib13","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1172\/JCI26132","article-title":"M-CSF mediates TNF-induced inflammatory osteolysis","volume":"115","author":"Kitaura","year":"2005","journal-title":"J Clin Invest"},{"key":"10.1016\/j.joms.2020.10.001_bib14","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0266-4356(93)90168-V","article-title":"Central giant cell granulomas of the jaws regress with calcitonin therapy","volume":"31","author":"Harris","year":"1993","journal-title":"Br J Oral Maxillofac Surg"},{"key":"10.1016\/j.joms.2020.10.001_bib15","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1136\/jcp.51.11.831","article-title":"Study of the cell biology and biochemistry of cherubism","volume":"51","author":"Southgate","year":"1998","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.joms.2020.10.001_bib16","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1055\/s-0039-1698923","article-title":"Treatment of cherubism with salmon calcitonin: A case report","volume":"5","author":"Etoz","year":"2011","journal-title":"Eur J Dent"},{"key":"10.1016\/j.joms.2020.10.001_bib17","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1016\/S1470-2045(19)30663-1","article-title":"Denosumab in patients with giant-cell tumour of bone: A multicentre, open-label, phase 2 study","volume":"20","author":"Chawla","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.joms.2020.10.001_bib18","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/CCO.0000000000000529","article-title":"Challenges of denosumab in giant cell tumor of bone, and other giant cell-rich tumors of bone","volume":"31","author":"Lipplaa","year":"2019","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.joms.2020.10.001_bib19","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1002\/jbmr.1603","article-title":"Denosumab treatment for fibrous dysplasia","volume":"27","author":"Boyce","year":"2012","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.joms.2020.10.001_bib20","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1002\/jbmr.2431","article-title":"The calcineurin inhibitor tacrolimus as a new therapy in severe cherubism","volume":"30","author":"Kadlub","year":"2015","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.joms.2020.10.001_bib21","doi-asserted-by":"crossref","first-page":"1278.e1","DOI":"10.1016\/j.joms.2019.02.021","article-title":"A Paradigm Shift in the management of cherubism? A Preliminary report using imatinib","volume":"77","author":"Ricalde","year":"2019","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.joms.2020.10.001_bib22","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1002\/jbmr.2125","article-title":"Etanercept administration to neonatal SH3BP2 knock-in cherubism mice prevents TNF-\u03b1-induced inflammation and bone loss","volume":"29","author":"Yoshitaka","year":"2014","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.joms.2020.10.001_bib23","first-page":"147","article-title":"Ineffectiveness of tumour necrosis factor-alpha inhibition in association with bisphosphonates for the treatment of cherubism","volume":"29","author":"Pagnini","year":"2011","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.joms.2020.10.001_bib24","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1002\/jbmr.3449","article-title":"Second-generation SYK inhibitor entospletinib Ameliorates Fully established inflammation and bone destruction in the cherubism mouse model","volume":"33","author":"Yoshimoto","year":"2018","journal-title":"J Bone Miner Res"},{"issue":"6 Pt 1","key":"10.1016\/j.joms.2020.10.001_bib25","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1542\/peds.103.6.1145","article-title":"Antiangiogenic therapy of a recurrent giant cell tumor of the mandible with interferon alfa-2a","volume":"103","author":"Kaban","year":"1999","journal-title":"Pediatrics"},{"key":"10.1016\/j.joms.2020.10.001_bib26","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.joms.2016.06.007","article-title":"Adjuvant antiangiogenic treatment for aggressive giant cell lesions of the jaw: A 20-year experience at Massachusetts general hospital","volume":"75","author":"Schreuder","year":"2017","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.joms.2020.10.001_bib27","doi-asserted-by":"crossref","DOI":"10.1186\/1746-160X-8-23","article-title":"Treatment of central giant cell lesions using bisphosphonates with intralesional corticosteroid injections","volume":"8","author":"da Silva","year":"2012","journal-title":"Head Face Med"},{"key":"10.1016\/j.joms.2020.10.001_bib28","unstructured":"Joint Formulary Committee, British National Formulary (online). London: BMJ Group and Pharmaceutical Press. Available at: http:\/\/www.medicinescomplete.com. Accessed November 4, 2020"},{"key":"10.1016\/j.joms.2020.10.001_bib29","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1159\/000365889","article-title":"The use of bisphosphonates in pediatrics","volume":"82","author":"Baroncelli","year":"2014","journal-title":"Horm Res Paediatr"},{"key":"10.1016\/j.joms.2020.10.001_bib30","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/jpc.13768","article-title":"Consensus guidelines on the use of bisphosphonate therapy in children and adolescents","volume":"54","author":"Simm","year":"2018","journal-title":"J Paediatr Child Health"},{"issue":"Suppl 1","key":"10.1016\/j.joms.2020.10.001_bib31","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1186\/1750-1172-7-S1-S3","article-title":"Pathophysiology and medical treatment of pain in fibrous dysplasia of bone","volume":"7","author":"Chapurlat","year":"2012","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.joms.2020.10.001_bib32","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1111\/bcp.13820","article-title":"Clinical and translational pharmacological aspects of the management of fibrous dysplasia of bone","volume":"85","author":"Rotman","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.joms.2020.10.001_bib33","doi-asserted-by":"crossref","first-page":"4133","DOI":"10.1210\/jc.2014-1371","article-title":"A randomized, double blind, placebo-controlled trial of alendronate treatment for fibrous dysplasia of bone","volume":"99","author":"Boyce","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.joms.2020.10.001_bib34","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.joms.2008.12.006","article-title":"Alternative Indications for bisphosphonate therapy","volume":"67","author":"Landesberg","year":"2009","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.joms.2020.10.001_bib35","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1186\/1471-2407-10-462","article-title":"Bisphosphonate treatment of aggressive primary, recurrent and metastatic Giant Cell Tumour of Bone","volume":"10","author":"Balke","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1016\/j.joms.2020.10.001_bib36","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ijom.2019.08.004","article-title":"Can children be affected by bisphosphonate-related osteonecrosis of the jaw? A systematic review","volume":"49","author":"Duarte","year":"2020","journal-title":"Int J Oral Maxillofac Surg"},{"key":"10.1016\/j.joms.2020.10.001_bib37","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1093\/rheumatology\/kex384","article-title":"How to use bisphosphonates safely and optimally","volume":"57","author":"Jagpal","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.joms.2020.10.001_bib38","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1359\/jbmr.0707onj","article-title":"Bisphosphonate-associated osteonecrosis of the jaw: Report of a Task Force of the American Society for bone and Mineral research","volume":"22","author":"Khosla","year":"2007","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.joms.2020.10.001_bib39","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1210\/jc.2010-0636","article-title":"Alendronate for the treatment of pediatric osteogenesis imperfecta: A randomized placebo-controlled study","volume":"96","author":"Ward","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.joms.2020.10.001_bib40","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1359\/JBMR.051006","article-title":"Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta","volume":"21","author":"DiMeglio","year":"2006","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.joms.2020.10.001_bib41","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s00774-013-0438-9","article-title":"Pamidronate treatment stimulates the onset of recovery phase reducing fracture rate and skeletal deformities in patients with idiopathic juvenile osteoporosis: Comparison with untreated patients","volume":"31","author":"Baroncelli","year":"2013","journal-title":"J Bone Miner Metab"},{"key":"10.1016\/j.joms.2020.10.001_bib42","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1469-8749.2008.03222.x","article-title":"Effects of bisphosphonates in children with osteogenesis imperfecta: An AACPDM systematic review","volume":"51","author":"Castillo","year":"2009","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.joms.2020.10.001_bib43","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/(SICI)1096-9926(199908)60:2<68::AID-TERA10>3.0.CO;2-H","article-title":"Transplacental effects of bisphosphonates on fetal skeletal ossification and mineralization in rats","volume":"60","author":"Patlas","year":"1999","journal-title":"Teratology"},{"key":"10.1016\/j.joms.2020.10.001_bib44","doi-asserted-by":"crossref","first-page":"280","DOI":"10.14310\/horm.2002.1319","article-title":"The use of bisphosphonates in women prior to or during- pregnancy and lactation","volume":"10","author":"Ioannis","year":"2011","journal-title":"Hormones"},{"key":"10.1016\/j.joms.2020.10.001_bib45","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00198-018-4672-9","article-title":"Pregnancy and newborn outcomes after exposure to bisphosphonates: A case-control study","volume":"30","author":"Sokal","year":"2019","journal-title":"Osteoporos Int"}],"container-title":["Journal of Oral and Maxillofacial Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278239120312131?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278239120312131?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T17:03:06Z","timestamp":1759510986000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278239120312131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S0278239120312131"],"URL":"https:\/\/doi.org\/10.1016\/j.joms.2020.10.001","relation":{},"ISSN":["0278-2391"],"issn-type":[{"value":"0278-2391","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adjuvant Alendronic Acid in the Management of Severe Cherubism: A Case Report and Literature Review","name":"articletitle","label":"Article Title"},{"value":"Journal of Oral and Maxillofacial Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.joms.2020.10.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Inc. on behalf of the American Association of Oral and Maxillofacial Surgeons","name":"copyright","label":"Copyright"}]}}